GLP-1 receptor agonists and inhibitors for GLP-1 degradation have been used successfully to treat type 2 diabetes; however, recent reports suggest an increased risk of pancreatitis and pancreatic cancer in patients chronically treated with some of these drugs. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.